University of Pennsylvania researchers presented a potential manufacturing route for high-concentration, subcutaneous-ready siRNA formulations by addressing membrane fouling and concentration polarization during ultrafiltration. The work aims to overcome a bottleneck that limits moving siRNA therapeutics from lyophilized hospital workflows to aqueous, home-administered dosing. The approach centers on tuning membrane surface properties to enhance electrostatic repulsion, improving flux and enabling higher final siRNA concentrations. The presentation was described as a proof-of-concept and is reported as published in the Journal of Membrane Science with sponsorship from Eli Lilly. For the field, this is a translational manufacturing advance rather than a clinical readout—but it directly impacts the scalability and patient adherence case for RNA therapeutics. If filtration performance can be translated to production, it could reduce formulation barriers that have historically slowed broader uptake of siRNA regimens.